Impact of Lipoprotein(a) Levels and Apolipoprotein(a) Isoform Size on Risk of Coronary Heart Disease

A practical question for Lp(a) testing and therapy is whether the apo(a) particle size matters independently, or whether it acts only through its effect on Lp(a) concentration. This study answered it.

The investigators found that apo(a) isoform size (the number of “kringle IV” repeats) explained 40–50 percent of the variation in Lp(a) levels, and that people in the top fifth of Lp(a) had roughly double the coronary risk. Critically, that risk was essentially unchanged after adjusting for isoform size — meaning the effect of particle size on heart disease works entirely through its effect on Lp(a) concentration. Concentration is what matters.

This carries a clean clinical implication: since isoform size cannot be altered by therapy and adds nothing once concentration is known, measuring it is unnecessary — lowering the absolute Lp(a) level should be the objective of any Lp(a)-targeted strategy.

We rate the evidence strong. It is a well-conducted genetic case-control analysis whose conclusion — concentration over size — has guided how the field measures and aims to treat Lp(a). It aligns with the larger Gudbjartsson study reaching the same verdict.